newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series

  • AIM ImmunoTech Inc. (NYSE American: AIM) will participate in the Webull Corporate Connect Webinar Series.
  • CEO Thomas K. Equels is scheduled to present on Thursday, November 12, 2026, at 2:40 PM ET.
  • Webull serves over 27 million registered users globally across 16 markets.
  • AIM ImmunoTech is an immuno-pharma company developing Ampligen (rintatolimod) for late-stage pancreatic cancer.
  • Ampligen is a dsRNA & highly selective TLR3 agonist immuno-modulator showing broad-spectrum activity in clinical trials.
  • The press release includes forward-looking statements subject to risks that could cause actual results to differ materially.
Company
AIM ImmunoTech Inc.
Keywords
NYSE:AIM, AIM ImmunoTech Inc., Immuno-Oncology, oncology, pancreatic cancer, cancer